πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

3,067 results for β€œHospital” Clear

  1. Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CML,Blast Phase

    phase 2 small molecule active

    1 trial

  2. Ensartinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Ensartinib

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  4. Ensartinib group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  5. Envafolimab

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  6. Envafolimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  7. Envafolimab Injection

    The First People's Hospital of Lianyungang

    Gastrointestinal Neoplasms

    phase 2 small molecule active

    1 trial

  8. Epo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Premature Infant

    phase 2 small molecule terminated

    1 trial

  9. Erlotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Erythropoietin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Premature Infants

    phase 2 small molecule completed

    1 trial

  11. Etoposide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  12. Etoposide

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  13. Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution Γ  diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporzΔ…dzania roztworu do wstrzykiwaΕ„ / do infuzji

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  14. Expanded , Activated NK cells

    Hospital Authority, Hong Kong

    Ewing Sarcoma

    phase 2 mab active

    1 trial

  15. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  16. Experimental: tislelizumab+anlotinib

    The First People's Hospital of Lianyungang

    Thymic Carcinoma

    phase 2 small molecule active

    1 trial

  17. FCN-437c+Fulvestrant

    The First People's Hospital of Lianyungang

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  18. FOLFOX/FOLFIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  19. FOLFOXIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Cancer

    phase 2 small molecule active

    1 trial

  20. FOLFOXIRI-based HAIC+Fuquinitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Neoplasms

    phase 2 small molecule completed

    1 trial

  21. FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  22. Famitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule on hold

    1 trial

  23. Faropenem

    Hospital Authority, Hong Kong

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  24. Faslodex 250 mg solution for injection., PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources